Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Other Non-Current Assets (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Other Non-Current Assets for 6 consecutive years, with $210883.0 as the latest value for Q1 2025.

  • On a quarterly basis, Other Non-Current Assets fell 44.14% to $210883.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $210883.0, a 44.14% decrease, with the full-year FY2024 number at $252550.0, down 39.76% from a year prior.
  • Other Non-Current Assets was $210883.0 for Q1 2025 at Ensysce Biosciences, down from $252550.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $838091.0 in Q2 2021 to a low of $82819.0 in Q2 2022.
  • A 5-year average of $487285.1 and a median of $481716.5 in 2023 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 19867.09% in 2021, then crashed 90.12% in 2022.
  • Ensysce Biosciences' Other Non-Current Assets stood at $754756.0 in 2021, then fell by 22.37% to $585883.0 in 2022, then fell by 28.45% to $419217.0 in 2023, then crashed by 39.76% to $252550.0 in 2024, then dropped by 16.5% to $210883.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Other Non-Current Assets are $210883.0 (Q1 2025), $252550.0 (Q4 2024), and $294217.0 (Q3 2024).